Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis

BACKGROUND: Different bone‐modifying agents like bisphosphonates and receptor activator of nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men with prostate cancer and bone metastases to prevent skeletal‐related events (SREs). SREs such as pathologic fractures, s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cochrane Database Syst Rev
Hlavní autoři: Jakob, Tina, Tesfamariam, Yonas Mehari, Macherey, Sascha, Kuhr, Kathrin, Adams, Anne, Monsef, Ina, Heidenreich, Axel, Skoetz, Nicole
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Ltd 2020
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8095056/
https://ncbi.nlm.nih.gov/pubmed/33270906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013020.pub2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky